CLASS II ONGOING Drug recall · Reported 29 Oct 2025 · FDA Enforcement Report

Niacin Extended-release Tablets, USP, 1,000 mg recalled

Lannett is recalling Niacin Extended-release Tablets, USP, 1,000 mg, distributed nationwide in the US. The recall was initiated on 10 Oct 2025 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot, expiry: 21264027A, Exp 10/30/2025; 22266446A, Exp 12/31/2025; 22266901A, Exp 02/28/2026; 22267553A, 22267554A, Exp 03/31/2026; 22267555A, Exp 02/28/2026; 22267992A, Exp 04/30/2026; 22267993A, 22267994A, Exp 05/31/2026
NDC62175-320, 62175-322
UPC0362175320469
Quantity recalled46,848 90-count bottles

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0096-2026
FDA event ID
97778
Recalling firm
Lannett, Seymour, IN
Brand
Niacin
Manufacturer
Lannett Company, Inc.
Classification
Class II
Status
Ongoing
Recall initiated
10 Oct 2025
FDA classified
22 Oct 2025
Reported
29 Oct 2025
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Potency & Assay

Timeline

10 Oct 2025Recall initiated by company
22 Oct 2025Classified by FDA+12 days
29 Oct 2025Published in enforcement report+7 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Failed Dissolution Specifications

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

Niacin Extended-release Tablets, USP, 1,000 mg, Rx Only, 90 Tablets per bottle, Distributed by: Lannett Company, Inc., Philadelphia, PA 19136. NDC: 62175-322-46

Where it was distributed

Nationwide in the USA

Nationwide

Questions about this recall

Why was it recalled?

Failed Dissolution Specifications

Which lots are affected?

Lot, expiry: 21264027A, Exp 10/30/2025; 22266446A, Exp 12/31/2025; 22266901A, Exp 02/28/2026; 22267553A, 22267554A, Exp 03/31/2026; 22267555A, Exp 02/28/2026; 22267992A, Exp 04/30/2026; 22267993A, 22267994A, Exp 05/31/2026

Where was it sold?

Nationwide in the USA

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Lannett

All 15
ReportedClassRecallCompanyReasonWhere
DrugCLASS IIDextroamphetamine Saccharate recalled by Lannett CompanyDextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate And Amphetamine SulfateLannettPackaging DefectsNationwide
DrugCLASS IINiacin Extended-release Tablets, USP, 1,000 mg recalledNiacinLannettPotency & AssayNationwide
DrugCLASS IIIPrimidone Tablets USP, 250mg recalled by Lannett CompanyPrimidoneLannettOtherNationwide
DrugCLASS IIDextroamphetamine Saccharate, Amphetamine Aspartate recalledDextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate And Amphetamine SulfateLannettOtherOH
DrugCLASS IILisdexamfetamine Dimesylate Capsules, 40 mg recalled by Lannett CompanyLisdexamfetamine DimesylateLannettPackaging DefectsNationwide

Other Niacin recalls

All 10